RADOX' Reduced Abdominal Distension and Oxygen Delivery
Launched by DR MICHAEL SCOTT · Jan 23, 2014
Trial Information
Current as of June 06, 2025
Unknown status
Keywords
ClinConnect Summary
Design pilot study, single arm controlled study Hypothesis Deep neuromuscular blockade provided intraoperatively for patients undergoing laparoscopic colorectal surgery will have an increase in oxygen delivery as measured by haemodynamic data using oesophageal doppler. Secondary hypotheses Deep muscular blockade will provide the same surgical operating conditions at lower abdominal inflation pressures. The patients will experience less pain postoperatively due to less forced distension of the peritoneum demonstrated by less analgesic requirements. Patients will therefore spend less time in ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients over 18 years of age
- • Planned elective major abdominal surgery for laparoscopic resection of colorectal cancer on the enhanced recovery programme with use of neuromuscular block Capacity to consent
- Exclusion Criteria:
- • Known oesophageal disease as a contraindication to using oesophageal Doppler probe
- • Known allergy/hypersensitivity to rocuronium, sugammadex or other drugs to be given in protocol.
- • Significant neuromuscular disease Insulin dependent diabetes with or without known autonomic dysreflexia
- • Any known dysautonomia
About Dr Michael Scott
Dr. Michael Scott is a distinguished clinical trial sponsor renowned for his commitment to advancing medical research and improving patient outcomes. With extensive expertise in clinical trial design and execution, Dr. Scott leads initiatives that prioritize innovative therapies and evidence-based practices. His collaborative approach fosters strong partnerships with research institutions and healthcare professionals, ensuring rigorous adherence to regulatory standards and ethical considerations. Dedicated to enhancing the understanding of treatment efficacy, Dr. Scott's work significantly contributes to the advancement of medical science and the development of new therapeutic options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guildford, , United Kingdom
Patients applied
Trial Officials
michael Scott, MB ChB
Principal Investigator
Royal Surrey County Hospital, Guildford, UK
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials